These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 10728060)

  • 61. Use of calcium channel blockers in prostate cancer: Friends or foe?
    Han QF; Ren XF; Wu L; Li T; Yao HC
    Int J Cardiol; 2016 Jan; 203():740-1. PubMed ID: 26587732
    [No Abstract]   [Full Text] [Related]  

  • 62. Calcium channel blockers.
    Weiner DA
    Med Clin North Am; 1988 Jan; 72(1):83-115. PubMed ID: 3276988
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Atenolol as a comparator in outcome trials in hypertension: a correct choice in the past, but not for the future?
    Dahlöf B; Devereux RB; Kjeldsen SE; Lyle PA; Zhang Z; Edelman JM
    Blood Press; 2007; 16(1):6-12. PubMed ID: 17453746
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Cardiovascular drug therapy in the elderly.
    Aronow WS; Frishman WH; Cheng-Lai A
    Cardiol Rev; 2007; 15(4):195-215. PubMed ID: 17575484
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Calcium antagonists].
    Garrote C; Alegría E
    Enferm Intensiva; 1995; 6(4):165-9. PubMed ID: 8715360
    [No Abstract]   [Full Text] [Related]  

  • 66. Gender, ethnicity, and genes in cardiovascular disease. Part 2: implications for pharmacotherapy.
    Schaefer BM; Caracciolo V; Frishman WH; Charney P
    Heart Dis; 2003; 5(3):202-14. PubMed ID: 12783634
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Endothelial dysfunction, angiotensin-converting enzyme inhibitors and calcium antagonists.
    López-Jaramillo P; Casas JP
    J Hum Hypertens; 2002 Mar; 16 Suppl 1():S34-7. PubMed ID: 11986891
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [International symposium "Calcium antagonists in the treatment of cardiovascular diseases"].
    Sidorenko BA
    Kardiologiia; 1991 Oct; 31(10):93-4. PubMed ID: 1684397
    [No Abstract]   [Full Text] [Related]  

  • 69. Calcium antagonists in cardiovascular care. Proceedings of the Second International Symposium. Basel, Switzerland, February 13-15, 1991.
    J Cardiovasc Pharmacol; 1991; 18 Suppl 10():S1-117. PubMed ID: 1724995
    [No Abstract]   [Full Text] [Related]  

  • 70. The calcium channel blocker scare. Lessons for the future.
    Lenfant C
    Circulation; 1995 Jun; 91(12):2855-6. PubMed ID: 7796490
    [No Abstract]   [Full Text] [Related]  

  • 71. Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study.
    Rejnmark L; Vestergaard P; Mosekilde L
    J Hypertens; 2006 Mar; 24(3):581-9. PubMed ID: 16467662
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Calcium channel blockers as therapeutic agents except for cardiovascular diseases].
    Kohara K
    Clin Calcium; 2004 Apr; 14(4):639-43. PubMed ID: 15577024
    [No Abstract]   [Full Text] [Related]  

  • 73. Atorvastatin + amlodipine: new drug. Just a commercial ploy.
    Prescrire Int; 2007 Jun; 16(89):105. PubMed ID: 17582926
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Amlodipine/atorvastatin: the first cross risk factor polypill for the prevention and treatment of cardiovascular disease.
    Frishman WH; Zuckerman AL
    Expert Rev Cardiovasc Ther; 2004 Sep; 2(5):675-81. PubMed ID: 15350169
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Calcium antagonist drugs in the management of cardiovascular disease.
    Smith H; McLean A
    Med J Aust; 1989 Sep; 151(5):302. PubMed ID: 2770612
    [No Abstract]   [Full Text] [Related]  

  • 76. Use of calcium channel blockers and angiotensin-converting enzyme inhibitors after cardiac transplantation.
    Rockx MA; Haddad H
    Curr Opin Cardiol; 2007 Mar; 22(2):128-32. PubMed ID: 17284992
    [TBL] [Abstract][Full Text] [Related]  

  • 77. New aspects of calcium antagonism in cardiovascular disease. Proceedings of a symposium. An official satellite to the Twelfth Congress of the European Society of Cardiology. Stockholm, Sweden, September 19, 1990.
    Am Heart J; 1991 Jul; 122(1 Pt 2):307-74. PubMed ID: 1675838
    [No Abstract]   [Full Text] [Related]  

  • 78. Calcium channel antagonist controversy: symposium at the Congress of the International Society of Cardiovascular Pharmacotherapy on March 30, 1999, in Amsterdam.
    Rutishauser W
    Cardiovasc Drugs Ther; 2000 Feb; 14(1):91-2. PubMed ID: 10755206
    [No Abstract]   [Full Text] [Related]  

  • 79. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Calcium channel blockers in diabetic subjects: innocent at last?
    Zoccali C
    Diabetes Nutr Metab; 1999 Aug; 12(4):249-51. PubMed ID: 10782749
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.